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Abstract
Our goal was to evaluate the therapeutic potential of a novel antibody to the insulin growth factor-1 receptor (IGF-1-R; AMG
479) in endometrial cancer cells. The endometrial cancer cell lines, ECC-1/PRAB72 and RL-95-2, were used. Treatment with
AMG 479 (0.02-200 nmol/L) resulted in inhibition of cell proliferation at 72 to 120 hours. Insulin growth factor-1 (0.15-7.5
nmol/L) stimulated growth in both cell lines (range of 15%-42%, P ¼ .0025-.0445), which could be blocked by pretreatment with
AMG 479 (mean of 29% for ECC-1/PRAB72, P ¼ .006-.007; mean of 36% for RL-95-2, P ¼ .0002-.0045). AMG 479 suppressed
IGF-1-R kinase activity in a dose-dependent manner. Cells treated with AMG 479 underwent either G1 (ECC-1/PRAB72) or G2
(RL-95-2) arrest. AMG 479 decreased human telomerase reverse transcriptase (hTERT) mRNA expression in both endometrial
cancer cell lines. Treatment with AMG 479 rapidly blocked IGF-1-induced phosphorylation of IFG-1-R, Akt, and p44/42. Thus,
manipulation of the IGF-1-R pathway may serve as a promising therapeutic strategy for the treatment of endometrial cancer.
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Introduction
Endometrial cancer is the 4th most common cancer among
women in the United States, and the death rate from this disease
has alarmingly increased by 227% over the past 10 years. Type
I or those tumors of endometrioid histology comprise 70% to
80% of cases and are thought to arise from persistent unop-
posed estrogen stimulation, either endogenous or exogenous.
Women who develop these tumors are typically perimenopau-
sal or postmenopausal and often have risk factors such as obe-
sity, hyperlipidemia, nulliparity, diabetes mellitus and insulin
resistance, polycystic ovarian syndrome (PCOS), hypertension,
and late-onset menopause. Obesity, which increases bioavailable
estrogen levels by enhancing the conversion of androstenedione
to estrone in peripheral adipose tissue, has been linked to a 5-fold
increased risk of endometrial cancer. Diabetes and insulin resis-
tance have been linked to a 2- to 3-fold increased risk of devel-
oping this disease.1-4
Prolonged exposure to unopposed estrogen secondary
to obesity results in excess proliferation and ultimately the
development of endometrial cancer. Estrogen acts through its
nuclear receptor and subsequently regulates transcription of a
variety of genes, including IGF-1. Cyclic changes in IGF-1
expression and signaling have been implicated in the regula-
tion of the menstrual cycle, with increased transcription of
IGF-1 in the proliferative phase as compared to the secretory
phase. Insulin growth factor-1 mediates its proliferative
effects on the endometrium through binding and activation
of the insulin growth factor-1 receptor (IGF-1-R), which
subsequently leads to activation of the phosphatidylinositol
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3-kinase (PI3K)/Akt pathway and mitogen-activated protein
kinase (MAPK) pathways.
The PI3K/Akt pathway is negatively regulated by phospha-
tase and tensin homolog (PTEN), and loss of PTEN expression
is one of the most common molecular abnormalities associated
with endometrial cancers. Loss of PTEN results in phosphory-
lation of Akt and ultimately, stimulation of cell growth and pro-
motion of cell survival. Increased expression of the IGF-1-R
has been found in endometrial hyperplasia and endometrial
cancer specimens as compared to proliferative endometrium.5
Insulin growth factor-1 receptor was shown to be highly phos-
phorylated in cases of endometrial hyperplasia and cancer but
not in proliferative endometrium, indicating increased activation
of this receptor.5 Activated IGF-1-R was associated with
increased Akt phosphorylation.5 In addition, higher fasting insu-
lin levels have been positively associated with type I endometrial
cancers in a prospective case-cohort study.6 Thus, given the
potential interplay between the IGF-1 signaling and the PI3K/
Akt and MAPK pathways, the IGF-1-R is a logical therapeutic
target for type I endometrial cancers.
AMG 479 (Amgen, Thousand Oaks, California) is a fully
human monoclonal antibody isolated against the human
IFG-1R and is currently being evaluated in phase II trials.7-10
The IGF-1-R is a transmembrane receptor tyrosine kinase.
Autophosphorylation of the IGF-1-R occurs after binding of the
IGF-1 or IGF-2 ligands. In total, 3 tyrosine residues (Tyr1131,
Tyr 1135, and Tyr1136) within the kinase domain are the ear-
liest major autophosphorylation sites, and phosphorylation of
these 3 sites is required for kinase activation.11-13 Preclinical
work in human pancreatic cell lines has shown that AMG
479 effectively blocks binding of IGF-1 and IGF-2 to the
IGF-1-R, without cross-reacting to the insulin receptor (IR),
resulting in decreased cell proliferation.14 In addition, AMG
479 has been found to inhibit IGF-1-R activity in pancreatic
carcinoma xenograft models, with a corresponding inhibition
of tumor growth.14 Given these promising results, our goal was
to evaluate the effect of AMG 479 on cell proliferation and
expression of key targets involved in IGF-1-R signaling in
endometrial cancer cell lines.
Methods
Cell Culture and Reagents
Two type I endometrial cancer cell lines, ECC-1/PRAB72
and RL-95-2, were used in these experiments. The ECC-1/
PRAB72 cell line was generously provided by Dr Leen J. Blok
(Erasmus Medical Center Rotterdam, The Netherlands). The
ECC-1/PRAB72 cell line is both estrogen- and progesterone-
sensitive and was derived after transfection with the human
progesterone receptor A (hPRA) and B (hPRB).15 The RL-
95-2 cell line expresses both the estrogen and the progesterone
receptors. Both cell lines were maintained in Dulbecco’s-
Modified Eagle’s Medium (DMEM) supplemented with 5%
fetal bovine serum (FBS), 300 mmol/L L-glutamine, 5 mg/mL
bovine insulin, 10 000 units/mL penicillin, and 10 000 mg/mL
streptomycin under 5% CO2. AMG 479 was provided as
a stock solution by Amgen Pharmaceuticals. Methyl
thiazolyl-diphenyl-tetrazolium (MTT) dye and anti-b-actin
antibody were purchased from Sigma-Aldrich (St Louis, Mis-
souri). The anti-phosphorylated-IGF-1-R, anti-total-IGF-1-R,
anti-phophorylated-AKT, anti-total-AKT, anti-phosphorylated-
p42/44, anti-total-p42/44 antibodies, the IGF-1-R activity
enzyme-linked immunosorbent assay (ELISA) kit, apoptosis
screening ELISA kit, and the caspase-3 ELISA kit were purchased
from Cell Signaling Technology (Beverly, Massachusetts).
Enhanced chemiluminescence Western blotting detection reagents
were purchased from Amersham Biosciences (Arlington Heights,
Illinois). All other chemicals were purchased from Sigma-Aldrich.
Cell Proliferation Assay
Cell proliferation was determined by a MTT assay. Briefly,
ECC-1/PRAB72 and RL-95-2cells (8  103) were plated onto
96-well culture plates for 24 hours. Cells were then treated with
varying doses of AMG 479 or IGF-1 alone and in combination
for 48, 72, 96, and 120 hours, using 0.5% stripped serum media.
For the combination experiments, cells were pretreated with
AMG 479 for 6 hours followed by the addition of IGF-1. Viable
cell densities were determined by metabolic conversion of the
dye MTT. Subsequently, the MTT assay results were read by
measuring the optical density at 595 nm. The effects on cell
proliferation of AMG 479, IFG-I, or both in combination were
calculated as a percentage of control cell growth obtained from
PBS (1%) treated cells grown in the same 96-well plates.
Insulin Growth Factor-1 Receptor Activity
Insulin growth factor-1 receptor activity was determined using
the PathScan1 Phospho-IGF-1-R b (Tyr1131) Sandwich
ELISA Antibody Pair Protocol (Cell Signaling Technology,
Danvers, Massachusetts) according to the manufacturer’s pub-
lished protocol. Briefly, ECC-1/PRAB72 and RL-95-2 cells
were cultured in 6-well plates for 24 hours and then starved
overnight. Cells were treated with AMG 479 at varying con-
centrations in 5% fetal calf serum supplemented media for 60
minutes or exposed to AMG 479 (0.3 mg/mL), IGF-1 or both
in combination in 0.5% stripped serum media for 15 minutes.
For the combination experiments, cells were pretreated with
AMG 479 for 3 or 6 hours followed by the addition of IGF-
1. Cells were then washed with cold PBS and lysed with cell
lysis buffer. The bicinchoninic acid (BCA) Protein Assay Kit
(Pierce, Rockford, Illinois) was used to determine the protein
concentration from the supernatant for each cell sample. A total
of 100 mL of sample diluent plus 30 mg of protein was added to
the ELISA plates and then incubated overnight at 4C. The
ELISA plates were washed with wash buffer followed by incu-
bation with the detection antibody, TMB substrate, and stop
solution, according to the manufacturer’s protocol. The ELISA
plates were read by measuring absorption at 450 nm within 30
minutes after adding the STOP solution.
Mendivil et al 833
Flow Cytometry
ECC-1/PRAB72 and RL-95-2 cell lines were plated at 2.5 
105 cells/well in 6-well plates in their corresponding media for
24 hours prior to treatment with AMG 479. Subsequently, the
cells were either treated with different concentrations of AMG
479 for 36 hours or starved overnight and then treated with 15%
serum and AMG 479 at varying concentrations for 36 hours.
Cells were collected, washed twice with PBS, fixed in a 90%
methanol solution, and then stored at 20C until flow cyto-
metric analysis was performed. On the day of analysis, the cells
were washed and centrifuged twice using cold PBS to remove
all traces of methanol. The cells were resuspended in 100 mL
PBS and 10 mL of RNase A solution (D-PBS, 250 mg/mL
DNase-free RNase A [Sigma-Aldrich], 10 mmol/L EDTA) fol-
lowed by incubation for 30 minutes at 37C. After incubation,
110 mL of propidium ioidide (PI; 100 mg/mL) stain was added
to each tube and allowed to incubate at 4C for at least 30 min-
utes prior to the analysis. Florescence was determined by flow
cytometry on a CyAn (Beckman Coulter) fluorescence-
activated cell sorter. ModFit (Verity Software House) was uti-
lized for the analysis that controlled for dead cells and debris.
Apoptosis Assay
Apoptosis was measured by caspase-3 activity using the PathS-
can Apoptosis Multi-Target Sandwich ELISA Kit (Cell Signal-
ing Technology, Danvers, Massachusetts) according to the
manufacturer’s published protocol. Both cell lines were cul-
tured in 6-well plates with the concentrations of 2 to 4  105
cells/well for 24 hours and then treated with AMG 479 at vary-
ing doses in 0.5% stripped serum for an additional 24 hours.
The cells were lysed and the protein concentrations were mea-
sured to confirm equal loading onto an ELISA plate. Reagents
were added as described by the manufacturer, and the ELISA
plates were read by measuring absorption at 450 nm.
Real-Time Reverse Transcription Polymerase Chain
Reaction
Cells were cultured for 24 hours and then treated with AMG
479 at varying doses in 0.5% stripped serum media for an addi-
tional 48 hours. Total RNA was isolated using the RNeasy kit
(Qiagen Corporation, Germantown, Maryland). The reverse
transcription and PCR reactions were performed using the
TaqMan Gold 1-step reverse transcription polymerase chain
reaction (RT-PCR) kit in the ABI Prism 7700 Sequence Detec-
tion System (Applied Biosystems, Foster City, California).
Reverse transcription was carried out at 48C for 30 minutes.
The PCR condition consisted of a 10-minute step at 95C and
40 cycles at 95C for 15 seconds and 65C for 1 minute.
A housekeeping control gene acidic ribosomal phosphoprotein
P0 (RPLP0, also known as 36B4) was used as an internal con-
trol to correct for the differences in the amount of RNA in each
sample. The standard curve for human telomerase reverse tran-
scriptase (hTERT) was generated by using dilutions of a known
amount of cRNA synthesized by in vitro transcription of a
cloned fragment. The normalized level of hTERT in each sam-
ple was estimated by a ratio of the hTERT level to the RPLP0
levelas described previously.16
Western Blot Analysis
The RL-95-2 and ECC-1/PRAB72 cells were plated at 2.5 
105 cells/well in 6-well plates for 24 hours. Cells were treated
with AMG 479, IFG-1, or both in combination at various time
points. For the combination experiments, cells were pretreated
with AMG 479 for 3 or 6 hours followed by the addition of
IGF-1. Equal amounts of protein were separated by gel electro-
phoresis and transferred onto a High Hybond Hydrophobic Ply-
vinylidene Difluoride (PVDF) membrane (GE Healthcare Life
Sciences, Piscataway, New Jersey). The membranes were
blocked with 5% nonfat dry milk, and then incubated with a
1:1000 dilution of primary antibody overnight at 4C. The
membrane was then washed and incubated with a secondary
peroxidase-conjugated antibody for 1 hour after washing. Anti-
body binding was detected using an enhanced chemilumines-
cence detection system (GE Healthcare Life Sciences,
Piscataway, New Jersey). Western blot films were digitized,
and band net intensities were quantified by a densitometer
using the Genegynome Image System (Sygene, Maryland).
Statistical Analysis
The results for experiments were normalized to the mean of the
control and analyzed using the Student’s t test. STATA soft-
ware (StataCorp, College Station, Texas) was used to perform
the statistical analyses.
Results
Sensitivity of Endometrial Cancer Cells to AMG 479
We examined the effect of AMG 479 on proliferation in 2
endometrial cancer cell lines. Treatment with AMG 479
(0.02-200 nmol/L) alone vs control (1% PBS) resulted in inhi-
bition of cell proliferation at 72 to 120 hours (mean of 21% for
ECC-1/PRAB72, P ¼ .0005-.0123; mean of 31% for RL-95-2,
P ¼ .0001-.0030) (Figure 1A and B). Treatment with IGF-1
(0.15-7.5 nmol/L) stimulated growth in both of these cell lines
(range of 15%-42%, P ¼ .0025-.0445) as compared to PBS-
treated controls. On the contrary, IGF-1-induced growth could
be effectively blocked by pretreatment with AMG 479 for 6
hours (mean of 29% for ECC-1/PRAB72, P¼ .006-.007; mean
of 36% for RL-95-2, P ¼ .0002-.0045; Figure 1C). The Stu-
dent’s t test was used to assess differences between groups.
Thus, AMG 479 can effectively suppress IGF-induced endo-
metrial cancer cell growth.
Effect of AMG 479 on IGF-1-R Activity
To assess the effect of AMG 479 on the activity of the IGF-1-R,
the phosphotyrosine levels (Tyr 1131) of the activated IGF-1-R
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were measured by ELISA. Treatment with AMG 479 alone
(0.02-200 nmol/L) for 1 hour significantly reduced IGF-1-R
activity in a dose-dependent manner in both of the endometrial
cancer cell lines (P ¼ .0030-.0377 for ECC-1/PRAB72,
P ¼ .0059-.0437 for RL-95-2) as compared to PBS-treated con-
trols (Figure 2A). As expected, the cells treated with IGF-1 alone
(3.7 nmol/L) for 15 minutes demonstrated a dramatic increase in
IGF-1-R kinase activity (P ¼ .0040 for ECC-1/PRAB72, P ¼
0.0060 for RL-95-2; Figure 2B). However, pretreatment
with AMG 479 (2 nmol/L) was able to potently block IGF-1
(0.15-7.5 nmol/L) stimulated autophosphorylation of the
IGF-1-R in both endometrial cancer cell lines (P ¼ .0050-
.0327 for ECC-1/PRAB72, P ¼ .0062-.0197 for RL-95-2;
Figure 2B). The comparison group was IGF-1 (3.7 nmol/L) sti-
mulated IGF-1-R kinase activity. The Student t test was used to
assess differences between groups. Similar results were found
after 3 and 6 hours of pretreatment with AMG 479 prior to expo-
sure to IGF-1. This indicates that AMG 479 can successfully inhi-
bit the kinase activity of the IGF-1-R, even in the presence of
increasing concentrations of IGF-1.
Effect of AMG 479 on Cell Cycle and Apoptosis
To characterize the mechanism of growth inhibition by AMG
479, the cell-cycle profile and induction of apoptosis was ana-
lyzed after treatment with AMG 479. The ECC-1/PRAB72
cells treated with AMG 479 underwent increased G1 arrest as
demonstrated by flow cytometric analysis (Figure 3B). In con-
trast, the RL-95-2 cells treated with AMG 479 underwent
increased G2 arrest (Figure 3A). The percentage change ranged
from 9% to 13% for the ECC-1/PRAB72 cell line and 11% to
13% for the RL-95-2 cell line as compared to PBS-treated con-
trols (Student t test, P¼ .008-.0090). In order to investigate the
impact of growth factors on control of the cell cycle by AMG
479, the cells were starved overnight and then treated with 15%
serum alone or in combination with AMG 479. As expected,
serum stimulation resulted in transition of cells from G1 to S
phase by 24 hours, with a concomitant decrease in G1 phase
(Figure 3C and D). AMG 479 significantly blocked serum-
induced entry to S phase, resulting in G1 cell-cycle arrest in the
ECC-1/PRAB72 cell line and G2 arrest in the RL-95-2 cell line
Figure 1. Effect of AMG 479 on proliferation of endometrial cancer cells. The ECC-1/PRAB72 (A) and RL-95-2 (B) cell lines were cultured in
the presence of varying concentrations of AMG 479 for 5 days. AMG 479 inhibited proliferation in both of these cell lines. Subsequently, both
endometrial cancer cell lines were pretreated with AMG 479 (6.6 nmol/L) for 6 hours and then exposed to insulin growth factor-1 (IGF-1; 3.7
nmol/L) for 72 hours. AMG 479 blocked IGF-1-induced cell proliferation in both of these cell lines (C). Relative growth of cells was determined
by MTT assay. The results are shown as the mean + SE of triplicate samples and are representative of 3 independent experiments (* Indicates
statistically significant difference.).
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(Figure 3C and D). The percentage change ranged from 13% to
19% for the ECC-1/PRAB72 cell line and 15% to 28% for the
RL-95-2 cell line as compared to the serum-stimulated control
(Student t test, P ¼ .0028-.0377). The effect of AMG 479 on
either G1 or G2 arrest appeared to be dose-dependent.
An apoptosis assay using an antibody to caspase-3 was per-
formed after exposure to AMG 479. Caspases are a family of
cysteine proteases that act in a cascade to trigger apoptosis.
Caspase-9 is an initiator caspase that is thought to activate the
effector caspases (caspase-3 and -6) involved in actual cell dis-
assembly. Caspase-3 is considered to be a specific marker for
epithelial apoptosis. AMG 479 increased apoptosis by almost
3-fold but only at higher doses of treatment (200 nmol/L) as
demonstrated by increased caspase-3 activity (P ¼ .0017;
Figure 4). Lower doses of AMG 479 had little effect on
caspase-3 activity in this cell line. For the RL-95-2 cell line,
there was no significant increase in caspase-3 activity at any
dose of AMG 479 (Figure 4). In order to exclude other
apoptotic targets involved, similar experiments were per-
formed to assess the activity of p53, Bcl-2, Poly(ADP-ribose)
Polymerase (PARP), and Bcl-2-Associated Death (BAD) in the
RL-95-2 cell line. Even at higher doses (200 nmol/L), AMG
479 had little effect on the activity of any of these markers of
apoptosis (data not shown).
These results suggest that AMG 479 predominantly
inhibits cell growth via cell-cycle arrest in these endometrial
cancer cell lines. This effect may involve either the G1 or the
G2 checkpoint, depending on the endometrial cancer cell line.
Induction of apoptosis may contribute to the anti-proliferative
effect of AMG 479 in some endometrial cancer cells, espe-
cially at higher but yet still clinically relevant doses of treat-
ment (200 nmol).17
Effect of AMG 479 on hTERT mRNA Level
The maintenance of telomere length via the expression of
telomerase is vital to the ability of cancer cells to remain pro-
liferative. The hTERT gene encodes the catalytic subunit of tel-
omerase. Human telomerase reverse transcriptase expression is
the rate-limiting determinant of the enzymatic activity of
human telomerase and is thought to be a sensitive marker of
telomerase function and cell proliferation. Real-time RT-
PCR was used to quantify hTERT mRNA expression in the
endometrial cancer cell lines. Treatment with AMG decreased
hTERT mRNA expression in a dose-dependent manner in
both cell lines at 24 hours (data not shown) and 48 hours
(Figure 5) (P ¼ .0040-.0377 for ECC-1/PRAB72,
P ¼ .0175-.0481 for RL-95-2). These data suggest that AMG
479 may inhibit telomerase activity by rapidly decreasing
hTERT mRNA levels. The measurement of hTERT mRNA
expression may be implicated as a biomarker for inhibition
of cell proliferation with AMG 479.
Effect of AMG 479 on IGF-1-R and its Downstream
Pathways
To investigate the mechanisms underlying the antiproliferative
activity of AMG 479, we characterized the effect of AMG 479
on IGF-1-R and its relevant downstream cell signaling targets.
Ligand-dependent signaling through the IGF-1-R leads to the
phosphorylation and activation of PI3K/Akt and MAPK, both
of which have been implicated in tumor cell proliferation and
survival. As would be expected, IGF-1 alone rapidly induced
phosphorylation of IGF-1-R within 5 minutes of exposure in
both of the endometrial cancer cell lines (Figure 6A and B).
This effect persisted for at least 6 hours after treatment. Simi-
larly, treatment with IGF-1 resulted in phosphorylation of both
Akt and MAPK (p42/44) after only 5 minutes of exposure.
There was little effect on total-IGF-1-R, total-Akt or total-
p42/p44 expression. To determine whether AMG 479 was
capable of blocking signaling by IGF-1, Western blots were
performed on cells treated with ligand in the presence or
absence of AMG 479 pretreatment. AMG 479 blocked the
Figure 2. The effects of AMG 479 on insulin growth factor-1 receptor
(IGF-1-R) activity. RL-95-2 and ECC-1/PRAB72 cells were starved over-
night and then treated with 5% fetal bovine serum (FBS) and varying con-
centrations of AMG 479 alone for 60 minutes (A), or treated with AMG
(2 nmol/L) in combination with IGF-1 for 15 minutes (B). The phospho-
tyrosine levels (Tyr 1131) of the activated IGF-1-R were measured by
enzyme-linked immunosorbent assay (ELISA). Treatment with AMG
479 alone significantly reduced IGF-1-R activity in a dose-dependent
manner in both of the endometrial cancer cell lines (A). As expected,
cells treated with IGF-1 alone (3.7 nmol/L) for 15 minutes demon-
strated a dramatic increase in IGF-1-R kinase activity (B). AMG 479
(2 nmol/L) was able to potently block IGF-1 (0.15-7.5 nmol/L)
stimulated autophosphorylation of the IGF-1-R in both endometrial
cancer cell lines (B). These results are representative of two2 indepen-
dent experiments (* Indicates statistically significant difference.).
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phosphorylation of IGF-1-R, Akt, and p42/44 induced by
IGF-1 (Figure 6C and D). AMG 479 decreased phosphorylation
of Akt by 1.5-fold in the ECC-1/PRAB72 and by 2.5-fold in
the RL-95-2 cell line, as determined by densitometric quantita-
tion. In parallel, phosphorylation of p42/44 was decreased by
1.4-fold in the ECC-1/PRAB72 and by 1.3-fold in the RL-95-2
cell line. Similar results were found after 3 and 6 hours of pre-
treatment with AMG 479 prior to exposure to IGF-1. Once
again, there was little effect on total-IGF-1-R, total-Akt, or
total-p42/p44 expression. Thus, antibody-mediated blockade of
ligand binding to the IGF-1-R by AMG 479 suppressed down-
stream signaling of the 2 principal IGF-1-mediated pathways,
the PI3K/Akt and MAPK pathways.
Discussion
AMG 479 is a fully monoclonal antibody against the IGF-1-R
that is under investigation in Phase II trials for colorectal, small
cell lung, breast and pancreatic cancer as well as Ewing’s
sarcoma.7-10 Our findings suggest that AMG 479 may also have
anti-tumor activity for endometrial cancer. We found that
AMG 479 was a potent inhibitor of IGF-1-stimulated cell pro-
liferation in 2 endometrial cancer cell lines, predominantly
through G1 and G2 cell-cycle arrest. In addition, AMG 479
Figure 3. Induction of cell-cycle arrest by AMG 479. RL-95-2 and ECC-1/PRAB72 cells were cultured for 24 hours and treated with AMG 479
at varying concentrations in 5% fetal bovine serum (FBS) for 36 hours (A and B) or starved overnight and then stimulated with 15% serum and
AMG 479 at the noted concentrations for 36 hours (C and D). Cell-cycle analysis was performed by flow cytometry. AMG 479 inhibited cell-
cycle progression by arrest in G1 phase in the ECC-1/PRAB72 cells, and G2/M phase in the RL-95-2 cells. Results shown are representative of 1
of the 3 independent experiments. Statistical significant results are indicated by a *, as determined using the Student t test.
Figure 4. The effects of AMG 479 on apoptosis. The RL-95-2 and
ECC-1/PRAB72 cells were cultured for 24 hours and then treated
with AMG 479 at the indicated concentrations for an additional 24
hours. Apoptosis was assessed using an antibody to caspase-3. AMG
479 increased apoptosis in the ECC-1/PRAB72 cell line but only at
high doses of treatment (200 nmol/L). Lower doses of AMG 479 had
little effect on caspase-3 activity in this cell line. For the RL-95-2 cell
line, there was no significant increase in caspase-3 activity at any dose
of AMG 479. The results are shown as the mean + SD and are
representative of 2 independent experiments (* indicates statistically
significant difference.).
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suppressed hTERT mRNA expression in both of these cell
lines. Finally, AMG 479 was able to potently block IGF-
1-stimulated autophosphorylation and kinase activity of the
IGF-1-R, resulting in subsequent inhibition of phosphorylation
of the 2 major downstream signaling targets of the IGF-1-R
pathway, Akt, and MAPK (p42/p44).
We have demonstrated that AMG 479 suppressed prolifera-
tion via G1 or G2 cell-cycle arrest, depending on the endome-
trial cancer cell line being evaluated (Figure 3). AMG 479 was
also able to induce apoptosis in 1 of the 2 endometrial cancer
cell lines. This effect was only seen at higher doses of treatment
(200 nmol/L); however, this dose is still in the clinically
therapeutic range (Figure 4).17 This suggests cell-cycle arrest
as opposed to cell death is most likely the predominant contri-
butor to the anti-proliferative effect of AMG 479 in endome-
trial cancer cells. Similar to our findings, AMG 479 as well
as other blocking antibodies to the IGF-1-R appears to have
varying effects on cell-cycle control and apoptosis even among
cell lines derived from the same type of tumor. In human pan-
creatic cell lines, the efficacy of AMG 479 was the conse-
quence of increased apoptosis in 1 cell line and decreased
proliferation in the other.14 Differential effects of the fully
human anti-IGF-1-R antibody, A12, were also found in human
prostate cancer cell lines grown as xenografts.18 A12 induced
G1 cell-cycle arrest in the androgen-dependent prostate cancer
cell line as opposed to G2 arrest in the androgen-independent
cell line.18 In addition, apoptosis was induced only in tumors
derived from the androgen-dependent prostate cancer cell
line.18 We confirm that induction of G2 arrest is an alternative
mechanism of action of blocking antibodies to the IGF-1-R.
Despite the varying effects of IGF-1-R blocking antibodies
on cell-cycle control and apoptosis among cancer cells, this had
Figure 5. AMG 479 decreased human telomerase reverse transcriptase (hTERT) mRNA expression in a dose-dependent manner in (A) ECC-1/
PRAB72 and (B) RL-95-2 cells. Both cells were cultured for 24 hours and then treated with the indicated concentrations of AMG 479 for an
additional 48 hours. Human telomerase reverse transcriptase expression was determined by real-time reverse transcription polymerase chain
reaction (RT-PCR). The results are shown as the mean + SE of 2 independent experiments (* indicates statistically significant difference.).
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little bearing on overall tumor regression in in vivo models14,18
and therefore will most likely not be important in regard to clin-
ical response and outcomes to these agents.
In this study, AMG 479 was found to decrease hTERT
expression in the endometrial cancer cell lines, which, to our
knowledge, is the first time AMG 479 has been linked to the
regulation of telomerase activity (Figure 5). Although we did
not assess telomerase activity directly, hTERT expression is
the rate-limiting determinant of the enzymatic activity of
human telomerase and is thought to accurately correspond to
telomerase function. Insulin growth factor-1 has been found
to stimulate telomerase activity in prostate cancer cell lines,
potentially through phosphorylation of hTERT by Akt and
subsequent upregulation of hTERT mRNA expression.19
Increased expression of IGF-1 and IGF-1-R has also been posi-
tively correlated with increased telomerase activity and a
higher cell proliferation index in endometrial cancer tumors.20
It is certainly reasonable to hypothesize that AMG 479 inhibits
the effects of IGF-1 on telomerase activity by blocking binding
of this ligand to the IGF-1-R. However, our experiments were
performed in the absence of exogenous IGF-1, suggesting that
AMG 479 may have a more direct effect on hTERT mRNA
transcription.
Despite the well-established link between obesity, insulin
resistance, and endometrial cancer, there have been few studies
in regards to the IGF-1-R pathway and the pathogenesis of
Figure 6. The effect of AMG 479 on IGF-1-R and its downstream cell signaling targets as assessed by Western immunoblotting. The ECC-1/
PRAB72 (A and C) and RL-95-2 (B and D) cell lines were cultured for 24 hours followed by starving for 12 hours. The cell media was replaced
with fresh media containing 0.5% stripped fetal bovine serum (FBS) and AMG 479 or IGF-1 as indicated. (A and B) IGF-1 activated IGF-1-R and its
signaling pathway. Insulin growth factor-1 (7.5 nmol/L) alone rapidly induced phosphorylation of IGF-1-R in both of the endometrial cancer cell
lines. Similarly, treatment with IGF-1 resulted in phosphorylation of both Akt and MAPK (p42/44) after only 5 minutes of exposure. (C and D)
AMG 479 blocked the phosphorylation of IGF-1-R, AKT, and p42/44 induced by IGF-1. Serum-starved ECC-1/PRAB72 and RL-95-2 cells were
pretreated with AMG 479 (6.6 nmol/L) for 3 hours and subsequently stimulated with different concentrations of IGF-1 for 15 minutes (þ, 0.15
nmol/L;þþ, 3.7 nmol/L;þþþ, 7.5 nmol/L). These results are representative of 2 independent experiments. There was little effect on total-Akt,
total-p42/p44, or total IGF-1-R expression in either of these experiments.
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this disease. As previously described, IGF-1 binds to the
extracellular domains of the IGF-1-R, resulting in activation
of its intracellular tyrosine kinase domain and autophosphory-
lation of the receptor. This effect was validated in the endome-
trial cancer cell lines (Figure 2). In addition, AMG 479 was
able to potently block IGF-1-induced autophosphorylation of
the IGF-1-R in both of these cell lines (Figure 2). Subsequently,
activated IGF-1-R phosphorylates its substrates, culminating in
the initiation of the proliferative and anti-apoptotic signal
transduction pathways, PI3K/Akt and MAPK. We confirmed
that IGF-1 rapidly induced phosphorylation of IGF-1-R fol-
lowed by phosphorylation of both Akt and MAPK (p42/p44)
in the endometrial cancer cell lines. Furthermore, AMG 479 was
successful in blocking ligand-stimulated phosphorylation of the
IGF-1-R, Akt, and MAPK (p42/p44). Thus, we clearly demon-
strate that AMG 479 is capable of preventing autophosphoryla-
tion of the IGF-1-R by IGF-1 in endometrial cancer cells and
more importantly that this leads to inhibition of critical down-
stream signaling targets involved in cell growth and survival.
We postulate that increased circulating estrogen levels sec-
ondary to obesity may result in increased signaling through the
IGF-1-R pathway in the endometrium of these high-risk women,
leading to type I endometrial cancers. Estrogen itself does not
increase IGF-1-R expression but progesterone has been shown
to downregulate IGF-1-R expression. In the normal endome-
trium, progesterone antagonizes the actions of estrogen and inhi-
bits estrogen-induced cell proliferation. Therefore, it may be the
imbalance of estrogen and progesterone in the endometrium that
results in overexpression of the IGF-1-R and stimulation of this
pathway in endometrial cancers. Unfortunately, body mass index
(BMI) or diabetic history has not been correlated with alterations
in IGF-1-R expression and activation. Thus, it remains to be
determined whether women who are obese and have evidence
of insulin resistance will be more susceptible to pharmacologic
suppression of IGF-1 signaling by AMG 479 than their normal
weight, nondiabetic counterparts.
While most women with endometrial cancer will be diag-
nosed with early-stage disease and have a high cure rate with
surgery alone, up to 25% of women will have advanced stage
disease and require additional treatment. Advanced or recurrent
endometrial cancer is notoriously difficult to treat with poor
response rates and dismal overall survival. Given the limited
success of traditional therapies with cytotoxic or hormonal
regimens, the search has been for novel agents that target spe-
cific cellular signaling pathways thought to be essential in
endometrial cancer progression and metastasis. Based on our
study, blockade of the IGF-1-R seems to be a viable chemother-
apeutic strategy for endometrial cancer. In addition, increased
efficacy has been shown in vitro and in vivo for AMG 479 as
well as other IGF-1-R-blocking antibodies when used in com-
bination with other cytotoxic agents, suggesting that AMG 479
may also serve as a chemosensitizer.14,21,22 This may invari-
ably hold true for endometrial cancer and is worthy of future
evaluation for this disease.
Of note, two other endometrial cancer cell lines were tested
with AMG 479 and were minimally affected by this treatment
(data not shown). The 2 cell lines were (1) Ishikawa which is an
ER-positive type I endometrial cancer cell line and (2) SPEC-2
which is an ER-negative type II endometrial cancer cell line.
ECC-1/PRAB72 and RL-95-2, the cell lines used in this study,
are both ER-positive. Given these findings, ER status does not
seem to be a predictor of responsiveness to AMG 479 and
more work needs to be done to elicit other potential biomar-
kers for sensitivity to this agent. In this pursuit, priority should
be given to the identification of biomarkers both within the
tumor and in the metabolic composition of the host that would
stratify women to who would achieve the best clinical
response to IGF-1-R inhibition and potentially individualize
care for this disease.
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